Role of inflammation in diabetic macular edema

Ophthalmologica

Volumn 232, Issue 3, 2014, Pages 127-135

  Noma, Hidetaka ^a,b   Mimura, Tatsuya ^c   Yasuda, Kanako ^a   Shimura, Masahiko ^a  

^a TOKYO MEDICAL UNIVERSITY HACHIOJI MEDICAL CENTER   (Japan)

^b Tokyo Women s Medical University   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Aqueous flare; Diabetic macular edema; Monocyte chemotactic protein 1; Pentraxin 3; Soluble intercellular adhesion molecule 1; Soluble vascular endothelial growth factor receptor 2

Indexed keywords

HEMOGLOBIN A1C; INTERCELLULAR ADHESION MOLECULE 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTRAXIN 3; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CCL2 PROTEIN, HUMAN; ICAM1 PROTEIN, HUMAN; SERUM AMYLOID P; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VEGFA PROTEIN, HUMAN;

AGED; AQUEOUS FLARE VALUE; ARTICLE; BLOOD EYE BARRIER; BLOOD VESSEL PERMEABILITY; CLINICAL ARTICLE; DIABETIC MACULAR EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; LASER FLARE CELL METER; MALE; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PIGMENT EPITHELIUM; PROTEIN FUNCTION; RETINA FOVEA; RETINA MACULA HOLE; RETINAL THICKNESS; VISUAL SYSTEM PARAMETERS; VITREOUS BODY; BLOOD RETINA BARRIER; CAPILLARY PERMEABILITY; DIABETIC RETINOPATHY; MACULAR EDEMA; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RETINA TEAR;

AGED; BIOLOGICAL MARKERS; BLOOD-RETINAL BARRIER; C-REACTIVE PROTEIN; CAPILLARY PERMEABILITY; CHEMOKINE CCL2; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERCELLULAR ADHESION MOLECULE-1; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL PERFORATIONS; SERUM AMYLOID P-COMPONENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VITREOUS BODY;

EID: 84927956189     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000364955     Document Type: Article

References (58)

1. Antcliff RJ, Marshall J: The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999; 14: 223-232.
2. Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR: A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007; 114: 1860-1867.
3. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, Boyer D, Heier JS, Abraham P, Thach AB, Lit ES, Foster BS, Kruger E, Dugel P, Chang T, Das A, Ciulla TA, Pollack JS, Lim JI, Eliott D, Campochiaro PA: Twoyear outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 2010; 117: 2146-2151.
4. Funatsu H, Noma H, Mimura T, Eguchi S, Hori S: Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology 2009; 116: 73-79.
5. Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T, Nishida K: Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008; 145: 854-861.
6. Noma H, Mimura T, Eguchi S: Association of inflammatory factors with macular edema in branch retinal vein occlusion. JAMA Ophthalmol 2013; 131: 160-165.
7. Noma H, Mimura T, Masahara H, Shimada K: Pentraxin 3 and other inflammatory factors in central retinal vein occlusion and macular edema. Retina 2014; 34: 352-359.
8. Sawa M, Tsurimaki Y, Tsuru T, Shimizu H: New quantitative method to determine protein concentration and cell number in aqueous in vivo. Jpn J Ophthalmol 1988; 32: 132-142.
9. Zaczek A, Hallnas K, Zetterstrom C: Aqueous flare intensity in relation to different stages of diabetic retinopathy. Eur J Ophthalmol 1999; 9: 158-164.
10. Valente AJ, Rozek MM, Sprague EA, Schwartz CJ: Mechanisms in intimal monocyte-macrophage recruitment. A special role for monocyte chemotactic protein-1. Circulation 1992; 86:III20-III25.
11. Roebuck KA: Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB (review). Int J Mol Med 1999; 4: 223-230.
12. Lu M, Perez VL, Ma N, Miyamoto K, Peng HB, Liao JK, Adamis AP: VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci 1999; 40: 1808-1812.
13. Grading diabetic retinopathy from stereoscopic color fundus photographs-An extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98: 786-806.
14. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98: 823-833.
15. Nguyen NX, Schonherr U, Kuchle M: Aqueous flare and retinal capillary changes in eyes with diabetic retinopathy. Ophthalmologica 1995; 209: 145-148.
16. Breviario F, d'Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A, Saccone S, Marzella R, Predazzi V, Rocchi M, et al: Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 1992; 267: 22190-22197.
17. Garlanda C, Bottazzi B, Bastone A, Mantovani A: Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005; 23: 337-366.
18. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, Pizzetti F, Maggioni AP, Moccetti T, Metra M, Cas LD, Ghezzi P, Sipe JD, Re G, Olivetti G, Mantovani A, Latini R: PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000; 102: 636-641.
19. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, Vago L, Pasqualini F, Signorini S, Soldateschi D, Tarli L, Schweiger C, Fresco C, Cecere R, Tognoni G, Mantovani A: Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004; 110: 2349-2354.
20. Souza DG, Soares AC, Pinho V, Torloni H, Reis LF, Teixeira MM, Dias AA: Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury. Am J Pathol 2002; 160: 1755-1765.
21. Deban L, Russo RC, Sironi M: Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol 2010; 11: 328-334.
22. Souza DG, Amaral FA, Fagundes CT, Coelho FM, Arantes RM, Sousa LP, Matzuk MM, Garlanda C, Mantovani A, Dias AA, Teixeira MM: The long pentraxin PTX3 is crucial for tissue inflammation after intestinal ischemia and reperfusion in mice. Am J Pathol 2009; 174: 1309-1318.
23. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L: VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-371.
24. Zhang SX, Wang JJ, Gao G, Shao C, Mott R, Ma JX: Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J 2006; 20: 323-325.
25. Spoerri PE, Afzal A, Li Calzi S, Shaw LC, Cai J, Pan H, Boulton M, Grant MB: Effects of VEGFR-1, VEGFR-2, and IGF-IR hammerhead ribozymes on glucose-mediated tight junction expression in cultured human retinal endothelial cells. Mol Vis 2006; 12: 32-42.
26. Agostini H, Boden K, Unsold A, Martin G, Hansen L, Fiedler U, Esser N, Marme D: A single local injection of recombinant VEGF receptor 2 but not of Tie2 inhibits retinal neovascularization in the mouse. Curr Eye Res 2005; 30: 249-257.
27. Lorquet S, Berndt S, Blacher S, Gengoux E, Peulen O, Maquoi E, Noel A, Foidart JM, Munaut C, Pequeux C: Soluble forms of VEGF receptor-1 and-2 promote vascular maturation via mural cell recruitment. Faseb J 2010; 24: 3782-3795.
28. Shibuya M, Yamaguchi S, Yamane A, Ikeda T, Tojo A, Matsushime H, Sato M: Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990; 5: 519-524.
29. Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou, D, Jia X, Kerbel RS: A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol Cancer Res 2004; 2: 315-326.
30. Hornig C, Barleon B, Ahmad S, Vuorela P, Ahmed A, Weich HA: Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest 2000; 80: 443-454.
31. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, Newsome WP, Jirousek MR, King GL: Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996; 98: 2018-2026.
32. He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB: Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem 1999; 274: 25130-25135.
33. Wu LW, Mayo LD, Dunbar JD, Kessler KM, Baerwald MR, Jaffe EA, Wang D, Warren RS, Donner DB: Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem 2000; 275: 5096-5103.
34. Olivera A, Edsall L, Poulton S, Kazlauskas A, Spiegel S: Platelet-derived growth factorinduced activation of sphingosine kinase requires phosphorylation of the PDGF receptor tyrosine residue responsible for binding of PLCgamma. FASEB J 1999; 13: 1593-1600.
35. Ghosh S, Baltimore D: Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature 1990; 344: 678-682.
36. Ledebur HC, Parks TP: Transcriptional regulation of the intercellular adhesion molecule-gene by inflammatory cytokines in human endothelial cells. Essential roles of a variant NF-kappa B site and p65 homodimers. J Biol Chem 1995; 270: 933-943.
37. Baldwin AS Jr.: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-683.
38. Marumo T, Schini-Kerth VB, Fisslthaler B, Busse R: Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NFkappaB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. Circulation 1997; 96: 2361-2367.
39. Boyle EM Jr., Kovacich JC, Canty TG, Morgan EN, Chi E, Verrier ED, Pohlman TH: Inhibition of nuclear factor-kappa B nuclear localization reduces human E-selectin expression and the systemic inflammatory response. Circulation 1998; 98:II282-II288.
40. Carnevale KA, Cathcart MK: Protein kinase C beta is required for human monocyte chemotaxis to MCP-1. J Biol Chem 2003; 278: 25317-25322.
41. Hong KH, Ryu J, Han KH: Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 2005; 105: 1405-1407.
42. Hao Q, Wang L, Tang H: Vascular endothelial growth factor induces protein kinase Ddependent production of proinflammatory cytokines in endothelial cells. Am J Physiol Cell Physiol 2009; 296:C821-C827.
43. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY: Vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 2001; 276: 7614-7620.
44. Basile A, Sica A, d'Aniello E, Breviario F, Garrido G, Castellano M, Mantovani A, Introna M: Characterization of the promoter for the human long pentraxin PTX3. Role of NF-kappaB in tumor necrosis factor-Alpha and interleukin-1beta regulation. J Biol Chem 1997; 272: 8172-8178.
45. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev 1997; 18: 4-25.
46. Claesson-Welsh L: Signal transduction by vascular endothelial growth factor receptors. Biochem Soc Trans 2003; 31: 20-24.
47. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996; 16: 4604-4613.
48. Pages G, Pouyssegur J: Transcriptional regulation of the vascular endothelial growth factor gene-A concert of activating factors. Cardiovasc Res 2005; 65: 564-573.
49. Oshika T, Kato S, Funatsu H: Quantitative assessment of aqueous flare intensity in diabetes. Graefes Arch Clin Exp Ophthalmol 1989; 227: 518-520.
50. Inoue M, Azumi A, Shirabe H, Tsukahara Y, Yamamoto M: Laser flare intensity in diabetics: correlation with retinopathy and aqueous protein concentration. Br J Ophthalmol 1994; 78: 694-697.
51. Moriarty AP, Spalton DJ, Moriarty BJ, Shilling JS, Ffytche TJ, Bulsara M: Studies of the blood-Aqueous barrier in diabetes mellitus. Am J Ophthalmol 1994; 117: 768-771.
52. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R: Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008; 92: 76-80.
53. Antonetti DA, Wolpert EB, DeMaio L, Harhaj NS, Scaduto RC Jr.: Hydrocortisone decreases retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem 2002; 80: 667-677.
54. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC: Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 2008; 57: 1026-1033.
55. Kurtz RM, Elner VM, Bian ZM, Strieter RM, Kunkel SL, Elner SG: Dexamethasone and cyclosporin A modulation of human retinal pigment epithelial cell monocyte chemotactic protein-1 and interleukin-8. Invest Ophthalmol Vis Sci 1997; 38: 436-445.
56. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adamis AP: Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 1999; 96: 10836-10841.
57. Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL 3rd, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, Sun JK: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064-1077.e1035.
58. Elman MJ, Bressler NM, Qin H, Beck RW, Ferris FL 3rd, Friedman SM, Glassman AR, Scott IU, Stockdale CR, Sun JK: Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118: 609-614.